Registry of Treatment Outcomes in a non-study population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223 (ROTOR-registry)

Registry of Treatment Outcomes in a non-study population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223 (ROTOR-registry).

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON19873

Enrollment

300

Registered

2015-03-16

Start date

2015-04-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radium-223

Interventions

This registry aims to evaluate the efficacy of Radium-223 treatment in a non-study population of CRPC patients treated earlier with Docetaxel and patients not treated earlier with Docetaxel and effica

Eligibility

Inclusion criteria

Inclusion criteria: 1. At the physicians discretion

Exclusion criteria

Exclusion criteria: 1. At the physicians discretion

Design outcomes

Primary

Measure	Time frame
1.To evaluate the efficacy of Radium-223 treatment in a non-study population by effects on Symptomatic Skeletal Event (SSE) 2. Evaluate Radium-223 treatment efficacy by patient reported analgesic use and pain outcome	—

Secondary

Measure	Time frame
1. Evaluate Radium-223 treatment efficacy in a non-study population of CRPC patients by clinical parameters. 2. Evaluate Radium-223 treatment tolerability in a non-study population of CRPC patients. 3. Evaluate the efficacy of the first subsequent therapy by clinical parameters 6. Identification of predictive clinical and explorative biomarkers of Radium-223 efficacy	—

Contacts

Public ContactS.K. Badrising

Netherlands Cancer Institute (NKI-AvL)

s.badrising@nki.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)